Daiwa Securities Starts Merck & Co. at Neutral With $70 Price Target
© MT Newswires 2021
| All news about MERCK & CO., INC. |
|
| 09:03a | Calliditas Therapeutics Starts Enrollment of Mid-Stage Head and Neck Cancer Study | MT |
| 07:35a | Berenberg Bank Adjusts Merck's Price Target to $95 From $87, Maintains Hold Rating | MT |
| 05/16 | Neoleukin Therapeutics Treats First Tumor Patient in Trial Evaluating NL-201 With Keytr.. | MT |
| 05/16 | Athenex, Merck Collaborate to Study Oraxol Plus Keytruda in Non-Small Cell Lung Cancer | MT |
| 05/16 | Rising Cyber Attacks Could Make Insurance Unaffordable | AQ |
| 05/13 | Tesla, Occidental rise; New Relic, Merck fall | AQ |
| 05/12 | Thinking about trading options or stock in Hess, Electronic Arts, Merck, Microsoft, or .. | PR |
| 05/11 | TRANSCRIPT : Merck & Co., Inc. Presents at Bank of America 2022 Healthcare Conference, May.. | CI |
| 05/10 | SECTOR UPDATE : Health Care Stocks Still Edging Higher This Afternoon | MT |
| 05/10 | Merck To Present Data at 2022 ASCO Annual Meeting Highlighting Promising Pipeline Medic.. | BU |
| |
|
| Analyst Recommendations on MERCK & CO., INC. |
|
| |
|
|
|
| Sales 2022 |
57 870 M
-
-
|
| Net income 2022 |
15 443 M
-
-
|
| Net Debt 2022 |
17 730 M
-
-
|
| P/E ratio 2022 |
15,1x |
| Yield 2022 |
3,02% |
|
| Capitalization |
233 B
233 B
-
|
| EV / Sales 2022 |
4,34x |
| EV / Sales 2023 |
4,26x |
| Nbr of Employees |
67 500 |
| Free-Float |
70,6% |
|
|
Duration :
Period :
|
Technical analysis trends MERCK & CO., INC.
| Short Term | Mid-Term | Long Term | | Trends | Bullish | Bullish | Bullish |
Income Statement Evolution
|
| Mean consensus |
OUTPERFORM |
| Number of Analysts |
26 |
| Last Close Price |
92,32 $ |
| Average target price |
95,54 $ |
| Spread / Average Target |
3,49% |
|
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
